Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 131.65% | -127.33% | 611.77% | 54.30% | -153.69% |
| Total Depreciation and Amortization | -11.01% | -3.54% | -23.99% | 0.00% | -0.22% |
| Total Amortization of Deferred Charges | 0.92% | 2.99% | 3.58% | 3.89% | 0.68% |
| Total Other Non-Cash Items | 18.48% | -24.62% | 3.64% | -0.65% | 4.03% |
| Change in Net Operating Assets | -569.01% | 116.53% | -843.81% | 76.27% | -63.32% |
| Cash from Operations | -330.06% | -113.07% | 2,340.22% | 108.32% | -375.88% |
| Capital Expenditure | -- | 27.03% | -202.04% | -512.50% | 60.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 27.03% | -202.04% | -512.50% | 60.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.17% | 57.97% | -87.85% | 2,233.81% | -82.87% |
| Repurchase of Common Stock | -- | 100.00% | -- | 100.00% | 53.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.92% | 58.76% | -87.91% | 2,293.43% | 106.85% |
| Foreign Exchange rate Adjustments | -171.20% | 736.36% | -96.79% | 90.81% | 137.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -375.30% | -111.77% | 837.67% | 122.05% | -467.20% |